Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

PURPOSE: In the MONALEESA-3 Phase III trial of patients with hormone receptor–positive human epidermal growth factor receptor–negative advanced breast cancer, ribociclib plus fulvestrant significantly improved progression-free survival (PFS) and overall survival (OS). Here, we present patient-report...

Descripción completa

Detalles Bibliográficos
Autores principales: Fasching, Peter A., Beck, J. Thaddeus, Chan, Arlene, De Laurentiis, Michele, Esteva, Francisco J., Jerusalem, Guy, Neven, Patrick, Pivot, Xavier, Bianchi, Giulia V., Martin, Miguel, Chandiwana, David, Lanoue, Brad, Ridolfi, Antonia, Wang, Yingbo, Rodriguez Lorenc, Karen, Nusch, Arnd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567051/
https://www.ncbi.nlm.nih.gov/pubmed/33065342
http://dx.doi.org/10.1016/j.breast.2020.09.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567051/
https://www.ncbi.nlm.nih.gov/pubmed/33065342
http://dx.doi.org/10.1016/j.breast.2020.09.008

Ejemplares similares